EHS
EHS

Prometheus Bio’s IPO raises $190M for inflammatory bowel disease R&D


Wall Street sign

Prometheus Biosciences is taking a precision medicine approach to developing drugs and diagnostics for inflammatory bowel disease. The IPO cash will fund support its pipeline of IBD drug candidates for specific patient subpopulations.

Source link

EHS
Back to top button